These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 37592398)

  • 1. Updates in Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD) in Children.
    Rupasinghe K; Hind J; Hegarty R
    J Pediatr Gastroenterol Nutr; 2023 Nov; 77(5):583-591. PubMed ID: 37592398
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pediatric metabolic (dysfunction)-associated fatty liver disease: current insights and future perspectives.
    Vimalesvaran S; Vajro P; Dhawan A
    Hepatol Int; 2024 Oct; 18(Suppl 2):873-883. PubMed ID: 38879851
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nonalcoholic Fatty Liver Disease in Children with Obesity: Narrative Review and Research Gaps.
    Furthner D; Weghuber D; Dalus C; Lukas A; Stundner-Ladenhauf HN; Mangge H; Pixner T
    Horm Res Paediatr; 2022; 95(2):167-176. PubMed ID: 34351306
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current perspectives on the pathophysiology of metabolic associated fatty liver disease: are macrophages a viable target for therapy?
    Kjær MB; George J; Kazankov K; Grønbæk H
    Expert Rev Gastroenterol Hepatol; 2021 Jan; 15(1):51-64. PubMed ID: 32878486
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metabolic-Associated Fatty Liver Disease: A Disastrous Human Health Challenge.
    Fouda S; Pappachan JM
    Endocrinol Metab Clin North Am; 2023 Sep; 52(3):xv-xvi. PubMed ID: 37495346
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fatty liver disease in children (MAFLD/PeFLD Type 2): unique classification considerations and challenges.
    Hegarty R; Kyrana E; Fitzpatrick E; Dhawan A
    Ther Adv Endocrinol Metab; 2023; 14():20420188231160388. PubMed ID: 36968656
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correlation of the pediatric metabolic index with NAFLD or MAFLD diagnosis, and serum adipokine levels in children.
    Lazo-de-la-Vega-Monroy ML; Preciado-Puga MD; Ruiz-Noa Y; Salum-Zertuche M; Ibarra-Reynoso LD
    Clin Res Hepatol Gastroenterol; 2023 May; 47(6):102137. PubMed ID: 37149032
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of lifestyle intervention on IGF-1, IGFBP-3, and insulin resistance in children with obesity with or without metabolic-associated fatty liver disease.
    Haldrup D; Wei C; Holland-Fischer P; Kristensen K; Rittig S; Lange A; Hørlyck A; Solvig J; Grønbæk H; Birkebæk NH; Frystyk J
    Eur J Pediatr; 2023 Feb; 182(2):855-865. PubMed ID: 36508014
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Survey of physicians' knowledge about pediatric nonalcoholic fatty liver disease in China.
    Gao XY; Yang YF; Li L; Xing YF; Wang YX; Li XY; Yang SH; Wang MY; Fan JG; Wang H
    J Dig Dis; 2024 Jun; 25(6):380-393. PubMed ID: 38992957
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Updates in fatty liver disease: Pathophysiology, diagnosis and management.
    Gofton C; George J
    Aust J Gen Pract; 2021 Oct; 50(10):702-707. PubMed ID: 34590082
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatologists' Awareness and Knowledge of NAFLD and the Familiarity with Renaming NAFLD to MAFLD.
    Alem SA; Fouad Y; AbdAllah M; Attia D; Kamal I; Said E; Gomaa A; Abd-Elsalam SM; Gaber Y
    Endocr Metab Immune Disord Drug Targets; 2024; 24(12):1445-1453. PubMed ID: 36306455
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metabolic Dysfunction-associated Fatty Liver Disease and Mortality Among Chinese Adults: a Prospective Cohort Study.
    Wang X; Wu S; Yuan X; Chen S; Fu Q; Sun Y; Lan Y; Hu S; Wang Y; Lu Y; Qu S; Wang L
    J Clin Endocrinol Metab; 2022 Jan; 107(2):e745-e755. PubMed ID: 34467980
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nonalcoholic fatty liver disease versus metabolic-associated fatty liver disease: Prevalence, outcomes and implications of a change in name.
    Ng CH; Huang DQ; Nguyen MH
    Clin Mol Hepatol; 2022 Oct; 28(4):790-801. PubMed ID: 35545437
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An international multidisciplinary consensus on pediatric metabolic dysfunction-associated fatty liver disease.
    Zhang L; El-Shabrawi M; Baur LA; Byrne CD; Targher G; Kehar M; Porta G; Lee WS; Lefere S; Turan S; Alisi A; Weiss R; Faienza MF; Ashraf A; Sundaram SS; Srivastava A; De Bruyne R; Kang Y; Bacopoulou F; Zhou YH; Darma A; Lupsor-Platon M; Hamaguchi M; Misra A; Méndez-Sánchez N; Ng NBH; Marcus C; Staiano AE; Waheed N; Alqahtani SA; Giannini C; Ocama P; Nguyen MH; Arias-Loste MT; Ahmed MR; Sebastiani G; Poovorawan Y; Al Mahtab M; Pericàs JM; Reverbel da Silveira T; Hegyi P; Azaz A; Isa HM; Lertudomphonwanit C; Farrag MI; Nugud AAA; Du HW; Qi KM; Mouane N; Cheng XR; Al Lawati T; Fagundes EDT; Ghazinyan H; Hadjipanayis A; Fan JG; Gimiga N; Kamal NM; Ștefănescu G; Hong L; Diaconescu S; Li M; George J; Zheng MH
    Med; 2024 Jul; 5(7):797-815.e2. PubMed ID: 38677287
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Validation of nonalcoholic fatty liver disease (NAFLD) related steatosis indices in metabolic associated fatty liver disease (MAFLD) and comparison of the diagnostic accuracy between NAFLD and MAFLD.
    Chen J; Mao X; Deng M; Luo G
    Eur J Gastroenterol Hepatol; 2023 Apr; 35(4):394-401. PubMed ID: 36695773
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact renaming non-alcoholic fatty liver disease to metabolic associated fatty liver disease in prevalence, characteristics and risk factors.
    Huang XJ; Yin M; Zhou BQ; Tan XY; Xia YQ; Qin CX
    World J Hepatol; 2023 Aug; 15(8):985-1000. PubMed ID: 37701916
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nonalcoholic fatty liver disease or metabolic dysfunction-associated fatty liver disease diagnoses and cardiovascular diseases: From epidemiology to drug approaches.
    Dongiovanni P; Paolini E; Corsini A; Sirtori CR; Ruscica M
    Eur J Clin Invest; 2021 Jul; 51(7):e13519. PubMed ID: 33583033
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metabolic dysfunction associated fatty liver disease: The new nomenclature and its impact.
    Tang SY; Tan JS; Pang XZ; Lee GH
    World J Gastroenterol; 2023 Jan; 29(3):549-560. PubMed ID: 36688021
    [TBL] [Abstract][Full Text] [Related]  

  • 19. From Nonalcoholic Fatty Liver Disease (NAFLD) to Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD)-New Terminology in Pediatric Patients as a Step in Good Scientific Direction?
    Flisiak-Jackiewicz M; Bobrus-Chociej A; Wasilewska N; Lebensztejn DM
    J Clin Med; 2021 Mar; 10(5):. PubMed ID: 33804296
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MAFLD: How is it different from NAFLD?
    Gofton C; Upendran Y; Zheng MH; George J
    Clin Mol Hepatol; 2023 Feb; 29(Suppl):S17-S31. PubMed ID: 36443926
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.